niraparib
14 products
37 abstracts
5 targets
Target
TNKS1Target
TNKS2Target
BRCATarget
PARP-2Target
STINGAbstract
Niraparib efficacy in patients with newly-diagnosed glioblastoma: Clinical readout of a phase 0/2 "trigger" trial.Org: Ivy Brain Tumor Center at Barrow Neurological Institute, Ivy Brain Tumor Center,
Abstract
Mind the gap: Estimating the opportunity lost due to the gap between FDA and EMA cancer drug approvals.Org: Lifespan Cancer Institute, Brown University School of Medicine-Rhode Island Hospital, Rhode Island Hospital, Stanford University School of Medicine, The University of Texas MD Anderson Cancer Center,
Abstract
Results and exploratory biomarker analyses of a phase II study CHANGEABLE: Combination of HX008 and niraparib in germ-line-mutated metastatic breast cancer.Org: Department of Medical Oncology, Fudan University Shanghai Cancer Center, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, China, Department of Oncology, Shanghai Medical College, Fudan University, Shanghai, Shanghai, China, State Key Laboratory of Oncogenes and Related Genes, Shanghai Cancer Institute, Shanghai, China, Department of Breast Surgery, Fudan University Shanghai Cancer Center, Shanghai, China,
Abstract
First-in-human, phase 1/2 study of GSK4524101, an oral DNApolymerase theta inhibitor (POLQi), alone or combined with the poly(ADP-ribose) polymerase (PARP) inhibitor (PARPi) niraparib in adults with solid tumors.Org: Stevenage, Uxbridge, Texas Oncology–San Antonio Babcock Next Oncology,
Abstract
Efficacy of niraparib in patients with advanced ovarian cancer: A meta-analysis of randomized controlled trials.Org: Federal University of the State of Rio de Janeiro, Rio De Janeiro, Faculdade Santa Marcelina, University of Brasilia, University of South Santa Catarina,
Abstract
Open-label, phase 2 study of adebrelimab combined with fuzuloparib in the treatment of patients with HRD-positive, recurrent platinum-resistant ovarian cancer.Org: Clinical Oncology School of Fujian Medical University,
Abstract
TTCC-2022-01: Niraparib and dostarlimab in locally-advanced head and neck squamous cell carcinoma treated with (chemo) radiotherapy (RADIAN).Org: Complejo Hospitalario de Navarra, Hospital Clinic Barcelona / IDIBAPS, IOB-Quirón, H. Germans Trias i Pujol, Vall d’Hebron Institut of Oncology (VHIO),
Abstract
Efficacy, safety, and biomarkers of neoadjuvant niraparib monotherapy in homologous recombination deficiency (HRD) advanced ovarian cancer: A prospective, multicenter, phase II, single-arm NANT study.Org: Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College Huazhong University of Science and Technology, Wuhan, China, Department of Gynecological Oncology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China, Department of Gynecology and Obstetrics, West China Second University Hospital, Sichuan University, Chengdu, China, Department of Gynecological Oncology, Sun Yat-sen University Cancer Center, Guangzhou, China, Department of Obstetrics and Gynecology, Qilu Hospital of Shandong University, Shandong University, Jinan, China,
Abstract
Phase 2, single arm clinical trial to evaluate the safety and activity of oregovomab and niraparib as a combinatorial immune priming strategy in subjects with platinum sensitive recurrent ovarian cancer: FLORA-4 study.Org: Department of OB/GYN, Duke Cancer Institute of Duke University Health System, CanariaBio, Inc,
Abstract
Risk assessment of myelosuppression with PARP inhibitors in prostate cancer: Insights from FAERS.Org: Cincinnati Children s Hospital Medical Center,
Abstract
A phase I study of highly potent oral ATR inhibitor (ATRi) tuvusertib plus oral PARP inhibitor (PARPi) niraparib in patients with solid tumors.Org: The University of Texas MD Anderson Cancer Center, Stem Cell Transplantation Rsch, Houston, TX, Newcastle University, Northern Centre for Cancer Care (NCCC), New Experimental Therapeutics (NEXT), Merck Serono Ltd.,
Abstract
Exploring the association of smoking status with clinical outcomes in patients with mPDAC treated on a clinical trial of maintenance niraparib plus immune checkpoint blockade.Org: Penn Medicine Abramson Cancer Center,
Abstract
A systematic literature review and indirect treatment comparison of PARP inhibitors in combination with next-generation hormonal agents in BRCA-mutated metastatic castration‑resistant prostate cancer.Org: Mtech Access,
Abstract
Niraparib and dostarlimab efficacy in patients with platinum-sensitive relapsed mesothelioma: MIST5, a phase IIa clinical trial.Org: Wythenshawe Hospital, Leicester Clinical Trials Unit - University of Leicester,
Abstract
Real-world overall survival in second-line maintenance niraparib monotherapy vs active surveillance in BRCA wild-type patients with recurrent ovarian cancer.Org: US Oncology Research/Sarah Cannon Research Institute, GOG-Foundation, GSK Research and Development Upper Providence, Collegeville, PA, Stephenson Cancer Center, University of Oklahoma Health Sciences Center/Sarah Cannon Research Institute,
Abstract
A phase 0/2 trigger trial of niraparib in patients with newly diagnosed glioblastoma.Org: Ivy Brain Tumor Center, Phoenix, AZ,
Abstract
Nipavect: Phase II study of niraparib and panitumumab in advanced RAS WT colorectal cancer.Org: Winship Cancer Institute of Emory University, Emory University, Atlanta, GA, USA, Emory University School of Medicine, Winship Cancer Institute, Emory University School of Medicine, Emory University Winship Cancer Institute,
Abstract
Targeting germline or somatic DNA repair defects (beyond BRCA) in pancreatic cancer with niraparib: A phase II study (NIRA-PANC).Org: University of Kansas Cancer Center, Kansas City, KS, Westwood, The University of Kansas Medical Center, Kansas City, MO, University of Kansas Medical Center, Department of Biostatistics & Data Science,
Abstract
Response to subsequent platinum-based chemotherapy post PARP inhibitor in recurrent epithelial ovarian cancer.Org: University of Ottawa, Ottawa, ON, Canada, OHRI, The Ottawa Hospital Research Institute,
Abstract
Phase II study evaluating the efficacy of niraparib and dostarlimab (TSR-042) in recurrent/metastatic head and neck squamous cell carcinoma (HNSCC) patients.Org: University of Cincinnati Medical Center, Mid-Florida Hematology Oncology, University of Cincinnati/University of Cincinnati Medical Center, University of Cincinnati College of Medicine, University of Cincinnati Cancer Institute,
Abstract
Toxicity profile and discordance between patients/physicians regarding niraparib maintenance in recurrent ovarian cancer (ROC) patients: Lessons from the NIQOLE real-life study—GINECO study.Org: Department of Medical Oncology, IRCCS Istituto Romagnolo per lo Studio dei Tumori (IRST) “Dino Amadori”, Meldola, Italy, Italy, Centre François Baclesse, CHRU Besançon - Hôpital Jean Minjoz, Clinique Tivoli-Ducos, Léon Bérard Cancer Center,
Abstract
Real-world data from a multi-center study: Insights to the efficacy and safety in patients with ovarian cancer (OC) received niraparib as first-line (1st-L) maintenance therapy (MT).Org: Zhongda Hospital, Southeast University, School of Medicine, Zhejiang University, Hangzhou, China, University of Science and Technology of China, Fudan University (Xiamen Branch), Jiangsu Cancer Hospital, Jiangsu Institute of Cancer Research,
Abstract
First trial of chemotherapy de-escalation in ovarian cancer (OC): A phase III randomized, open label study of niraparib maintenance after carboplatin and paclitaxel in patients with optimally debulked advanced (homologous recombination deficient) HRD high-grade ovarian cancer in first line therapy (N-PLUS/NOGGO-ov53/ENGOT-ov62).Org: Charite-Universitätsmedizin Berlin, Department of Gynecology with Center for Oncological Surgery, Campus Virchow Klinikum, Berlin, Germany, Stanford University School of Medicine, Institute for Biometry and Clinical Epidemiology, Hospital Universitario Virgen del Rocío, Sant'Anna Hospital,
Abstract
Phase II study of niraparib in patients with advanced melanoma with genetic homologous recombination (HR) mutation/alteration.Org: California Pacific Medical Center Research Institute, San Francisco, CA, San Francisco Department of Public Health,
Abstract
Neoadjuvant PARP inhibitors in patients with early HER2-negative breast cancer harboring BRCA 1/2 germline mutations: A systematic review and meta-analysis.Org: Universidade Estadual do Centro Oeste - UNICENTRO, Guarapuava, Brazil, Princess Margaret Hospital, Division of Medical Oncology and Hematology, Princess Margaret Cancer Centre, University Health Network, University of Toronto, Catholic University of Pelotas, Universidade de Brasília,
Abstract
TABLET: Relative bioavailability and bioequivalence study of niraparib tablets and capsules in patients with advanced solid tumors.Org: Sarah Cannon Research Institute at HealthONE, Denver, CO, START San Antonio, San Antonio, TX, START Midwest, Grand Rapids, MI, Emory University School of Medicine, Atlanta, GA, Sarah Cannon Research Institute, Tennessee Oncology, Nashville, TN,
Abstract
A randomised phase II trial of niraparib versus active symptom control in patients with previously treated mesothelioma: NERO.Org: Cancer Research UK Clinical Trials Unit, University of Southampton, University of Leicester and Leicester University Hospitals, Southampton Clinical Trials Unit, University Hospital Southampton NHS Foundation Trust,
Abstract
PARPi monotherapy as first-line maintenance following chemotherapy + bevacizumab in advanced ovarian cancer.Org: South Carolina Oncology Associates, Precision Q, Integra Connect, GSK Research and Development Upper Providence, Collegeville, PA,
Abstract
Efficacy and safety of niraparib maintenance therapy in patients with newly diagnosed advanced ovarian cancer who had measurable residual disease: A post-hoc subgroup analysis of the PRIME study.Org: Qilu Hospital of Shandong University, Jinan, China, National Cancer Center/National Clinical Research Center for Cancer/Cancer Hospital, Chinese Academy of Medical Sciences and Peking Union Medical College, Beijing, China, Cancer Hospital of the University of Chinese Academy of Sciences, Hangzhou, China, West China Second University Hospital, Sichuan University, Chengdu, Sichuan, China, Hunan Cancer Hospital, The Affiliated Cancer Hospital of Xiangya School of Medicine, Central South University, Changsha, China,
Abstract
Predictors of long-term progression-free survival (PFS) in niraparib-treated patients (pts) from the PRIMA/ENGOT-OV26/GOG-3012 study.Org: Medical University of South Carolina Hollings Cancer Center, Institut Català d’Oncologia L’Hospitalet de Llobregat, Hospital Duran i Reynals, IDIBELL, Grupo Español de Investigación en Cáncer de Ovario (GEICO),
Abstract
Tumor sensitization to PARP inhibitors by DNA damaging synthetically lethal acylfulvenes.Org: Lantern Pharma,
Abstract
Using chemotherapy response by KELIM score to predict response to first line maintenance PARP inhibitor therapy in non-BRCA mutant/homologous recombination deficiency (HRD) unknown high grade serous ovarian cancer (HGSOC).Org: BC Cancer-Vancouver Centre, University of British Columbia,
Abstract
A combination of niraparib plus anlotinib in patients with platinum-resistant ovarian clear cell carcinoma: Results of a single-arm phase II study (CC-ANNIE study).Org: Sun Yat-Sen Memorial Hospital, Guangzhou JOYO Pharma, China National Biotec Group, Department of Radiology, The First Affiliated Hospital, Sun Yat-sen University, Guangzhou, China, Sun Yat-sen Memorial Hospital of SunYat-sen University, Guangzhou, China,
Abstract
Maintenance therapy with a poly(ADP-ribose) polymerase inhibitor (PARP) in patients with newly diagnosed ovarian cancer: A systematic review and meta-analysis.Org: Centro de Oncologia do Parana, Princess Margaret Hospital, Catholic University of Pelotas, Universidade de Brasília, UNICENTRO,
Abstract
Real-world outcomes of first-line maintenance with niraparib or bevacizumab in advanced ovarian cancer.Org: Precision Q, Integra Connect, GSK Research and Development Upper Providence, Collegeville, PA, South Carolina Oncology Associates,
Abstract
Effect of testing for BRCA1/2 on outcomes in patients with ovarian cancer treated with PARPi in 1st line maintenance (1LM).Org: Florida Cancer Specialists/Sarah Cannon Research Institute, Sarasota, FL, Integra Connect PrecisionQ, Illumina, Inc., Integra Connect,
Abstract
Efficacy of PARP inhibitors in patients with metastatic castration resistant prostate carcinoma: A meta-analysis of phase III randomized controlled trials.Org: Community Hospital of San Bernardino, Abbott Northwestern Hospital, SSM St Mary's hospital, University of California Riverside, SSM St Louis University hospital,
Product
AKEEGAProduct
niraparib plus radiotherapyProduct
Basroparib (STP1002)Product
mPARPiProduct
dostarlimab + niraparibProduct
niraparib, bevacizumabProduct
niraparib + anlotinibProduct
niraparib + dostarlimabProduct
oregovomab + niraparibProduct
niraparib + bevacizumabProduct
targeted therapies